Revolutionizing Lung Cancer Detection: The Role of AI-Derived CAD Software

By Danélia Botes

July 12, 2023

Artificial Intelligence (AI)-derived computer-aided detection (CAD) software may be a game-changer in the field of lung cancer screening. These technologies can potentially enhance the detection and measurement of lung nodules in CT scan images, making them a cost-effective solution. However, more evidence is needed to ascertain which technologies are the most clinically and cost-effective.

There is little clinical-effectiveness evidence available on any of the individual technologies which means that more research is needed to fully understand the potential benefits and drawbacks of these technologies. For example, the software could potentially identify more people with benign lung nodules, leading to unnecessary anxiety and CT surveillance. 

Despite these uncertainties, the potential benefits of AI-derived CAD software cannot be ignored. Not only can it potentially increase the detection of lung nodules, but it can also improve reporting of nodule characteristics, assess the growth of lung nodules, and reduce the time to review and report CT scans. 

NICE encourages centres using AI-derived CAD software as part of targeted lung cancer screening to continue generating evidence and sharing their findings. This will help to realise the full potential of these technologies and facilitate comparisons between different software.

Recommendations for further research on the effect of using the software on clinical decision making and the effect of using the software on scan review and reporting time, are listed in the guideline.

Reference url

Recent Posts

Cost and clinical impact of MIS-C

Understanding the Cost and Clinical Impact of Multisystem Inflammatory Syndrome in Children (MIS-C)

🔍 Discovering the Economic Impact of Multisystem Inflammatory Syndrome in Children (MIS-C) 🏥💰

Understanding the cost and clinical impact of MIS-C during COVID-19 is crucial for healthcare providers and policymakers. Learn about treatment costs, patient outcomes, and key statistics related with MIS-C.

🌟#Healthcare #MIS-C #COVID19 #Pediatrics #HealthEconomics #MedicalResearch #HealthcareResearch #MedicalEconomics 📊

Let’s navigate the intersection of healthcare and economics together! 💼 #HealthcareInsights #EconomicAnalysis 🧠


Striking the Balance: Optimising Hepatitis B Treatment Strategies in The Gambia

Hepatitis B continues to pose a significant public health challenge, but the World Health Organization continues to work towards achieving their ambition of eliminating HBV as a public health problem by 2030.

One strategy is the Treat All approach, which sounds promising – however, in low-resource settings implementing promising strategies becomes more complex. This study explores striking the balance between promising strategies and getting people the treatment they need.

Learn more about innovative HBV treatment approaches and their impact on global health. Stay informed and join the conversation! 💡🔬 #HealthcareInnovation #HBVResearch

cost effectiveness multiple sclerosis

Cost-Utility and Cost-Effectiveness of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis

Exploring the Cost-Utility of MS Treatments: A Comprehensive Review 🧠💼 Dive into the latest findings on the cost-effectiveness of Disease-Modifying Drugs for Multiple Sclerosis. Discover key insights and recommendations for optimizing treatment strategies. #MSresearch #HealthcareEconomics #Neurology #HealthTech 📊🔬

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.